Mylan demands payback from Strides on plants targeted by FDA

Tracy Staton Mylan recently got hammered by the FDA in a warning letter for three plants that it acquired as part of its $ 1.75 billion acquisition of the sterile injectables business ...

FDA panel dashes Merck’s hopes for broader use of Zetia, Vytorin

Tracy Staton In a blow for Merck & Co.'s cholesterol franchise, an FDA advisory panel shot down its bid to tout Vytorin and Zetia as preventives ...

Merck poised to win bigger market for cholesterol-fighting Zetia

Tracy Staton Merck & Co.'s cholesterol drug Zetia gets another day in the spotlight on Monday. An FDA advisory panel is debating results from an outcomes trial, Improve-It, ...

Bayer looks to bone up in oncology after slipping behind rivals

Damian Garde German pharma giant Bayer is playing catch-up in the field of cancer treatments, expanding its efforts in hopes of cutting in on the burgeoning oncology market. FierceBiotech ...

Startup raises $15M to turn an old diabetes drug into a potent cancer killer

Damian Garde A group of scientists at UCLA have cooked up some compounds that could harness the cancer-fighting properties of metformin while avoiding the biological hurdles that have ...

‘Pfizergan’ talks prompt new anti-tax inversion rules from Treasury

Tracy Staton The U.S. Treasury Department is rushing out a new set of guidelines on the "tax inversion" deals that have allowed drugmakers to save big money on taxes by buying ...

Valeant posts 36% growth amid pricing scrutiny; may sell neurology biz

Carly Helfand Valeant may be the subject of current government scrutiny, and it may have recently suffered a stock-price freefall. But the company gave investors some good news ...

FDA’s review of BI’s Pradaxa was ‘lax’ and ‘permissive,’ watchdog claims

Carly Helfand Boehringer Ingelheim's next-gen anticoagulant, Pradaxa, has been plagued by safety worries that have cropped up since its 2010 FDA approval. And according to one watchdog ...

J&J says it has plenty of firepower for M&A, buyback or no buyback

Carly Helfand Johnson & Johnson may be embarking on a $ 10 billion share repurchase program, but that doesn't mean it doesn't have room to make deals. FiercePharma News

Endo’s generics unit Qualitest recalls gout, blood pressure meds

Eric Palmer Endo's Alabama plant where its Qualitest unit makes generics is recalling a couple of drugs, some for being outsized and off-color. FiercePharma News

Feds clamp a hold on Forum’s PhIII Alzheimer’s study following GI events

John Carroll The FDA has slammed the brakes on the late-stage Alzheimer's development program for encenicline after investigators reported a "small" number of serious ...

Just wait, Perrigo investor urges. We can get the same return–without a Mylan deal

Carly Helfand All eyes are on Perrigo's investors, who will have to decide whether to accept Mylan's offer when the wannabe acquirer takes it to them next Monday. And Israeli ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS